Skip to main content
Premium Trial:

Request an Annual Quote

Plexpress, MediSapiens Ink Gene Express Data Analysis Deal

NEW YORK (GenomeWeb News) – Plexpress today said that it has teamed up with MediSapiens to offer a new gene expression service that combines the firms' technologies.

Under the alliance, MediSapiens' IST Online Gene Expression Database had been combined with Plexpress' TRAC platform for high-throughput gene expression analysis. The firms said that they have launched the resulting OncoTrac Gene Expression Service, providing a "complete solution" from gene discovery and validation to studies across biomarker discovery, drug development, and life science research applications.

Plexpress CEO Jari Rautio said in a statement that the TRAC technology is ideal for use after genomic discovery with the MediSapiens database, which contains more than 20,000 samples and 300 million data points. The TRAC technology enables multiplex analysis of up to 30 genes in hundreds to thousands of samples. "In this way, researchers can really investigate the biology of their system in considerable depth, without sacrificing the number of genes they can assay in each sample," Rautio added.

Helsinki, Finland-based Plexpress is a spinoff of the Finnish Technology Research Center. MediSapiens, also based in Helsinki, specializes in cloud computing and genomic data mining and claims that its IST Online Gene Expression viewer is the world's largest unified gene expression database.

Financial and other terms of the alliance were not disclosed.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.